Participated · Seed · Jul 2026

Immitra Bio is developing scalable, one-time curative in-vivo gene editing therapies built around a mutation-agnostic editing approach and a digital target discovery platform. Its lead candidate, IB-003, is being developed as a potential one-time curative in-vivo gene editing treatment for an inherited anemia. The company's approach is designed to avoid complex ex-vivo cell manipulation, patient conditioning, and stem cell transplantation, aiming to enable off-the-shelf formulations that treat all patients within a given disease regardless of underlying mutation. Immitra Bio says its platform could generate dozens of differentiated therapeutic assets more quickly than highly personalized approaches. The recent CHF 2.4 million pre-seed financing will primarily fund preclinical proof-of-concept work for IB-003 and support additional discovery and validation across the pipeline and platform refinement. The company highlights scalability and commercial viability as core objectives for its technology.

Participated · Series A · Jul 2026

CCRAFT commercializes and manufactures TFLN-based photonic chips, operating what it describes as the world’s first independent TFLN foundry in Neuchâtel. The company began commercializing the technology in April 2025, based on more than six years of R&D carried out at CSEM, and has produced photonic chips for more than 40 partners worldwide through prior pilot production. CCRAFT currently serves customers across four continents and aims to scale its production platform to a capacity of up to 2,000 wafers per month by 2030. Financially, the company has just raised $7.8 million in private capital and secured more than $3.5 million in public and cantonal funding, totaling roughly $11.3 million in fresh capital to accelerate industrial-scale manufacturing. CCRAFT positions itself to capture demand from the growing photonic integrated circuits market and to establish a leading global manufacturing position in TFLN photonics.

Participated · Seed · Apr 2026

Cosaic develops a new category of food ingredients using yeast fermentation to provide creaminess, stability and functional performance in one ingredient, aiming to reduce reliance on multiple components and additives. The company positions its platform to help food and beverage manufacturers address formulation trade-offs between clean label, sensory performance, and cost. Cosaic employs 15 people and is in a pre-Series A stage, preparing for U.S. market entry next year. Its recent partnership with Ingredion and strategic investment from dsm-firmenich Ventures serve as commercial and strategic validation. The startup plans to use recent funding to complete regulatory work, scale production, and run industrial trials with large clients as it moves toward launch readiness.

Participated · Series A · Mar 2026

Seprify engineers a proprietary cellulose-based materials platform that replaces titanium dioxide, a widely used but increasingly regulated whitening and opacifying additive. Its flagship grades include SilvaLuma, an SPF-boosting ingredient for cosmetics and personal care, and SilvaAlba, a food-grade whitening solution. The platform has been validated at technology-readiness levels 7–9 through collaborations with industrial partners and is now moving through supplier qualification, early commercial contracts and procurement negotiations. More than 100 customer organisations are actively evaluating or purchasing the material, demonstrating early market traction. Near-term priorities focus on guaranteeing consistent quality and supply for cosmetics, personal care, food and pet food markets, while scaling production for higher-volume segments such as coatings, inks and printed electronics. The company holds a broad intellectual-property portfolio covering process, product and end-use applications. Although still pre-scale, the recent capital infusion positions Seprify to transition from pilot to commercial manufacturing and meet large industrial demand.

Participated · Seed · Mar 2026

Founded in May 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics builds technologies that dramatically lower the cost and increase the throughput of RNA sequencing. Its flagship BRB-seq and DRUG-seq platforms can prepare up to 1,536 RNA samples in a single tube, with DRUG-seq eliminating the need for RNA isolation altogether. These kits allow pharmaceutical and research customers to run primary drug screens, exploratory toxicology studies, and large-scale biomarker discovery projects that were previously cost-prohibitive. The company is now commercializing the 1,536-well MERCURIUS DRUG-seq kit while also developing new RNA-seq technologies and proprietary transcriptomic data assets to support AI/ML research. Alithea’s solutions target the growing demand for “big RNA data,” aiming to be the foundational data engine for next-generation therapeutics. Recent leadership changes elevated Chairman Frederik Decouttere to CEO, enabling co-founder Riccardo Dainese to focus on market expansion as CCO. No revenue or user metrics were disclosed, but the fresh seed capital underpins the firm’s push toward broad commercialization and further R&D.